Boston Scientific Invests in Bioresorbable Stent Startup Amaranth Medical
January 14, 2014
January 14, 2014 — Amaranth Medical announced the closing of an equity investment by Boston Scientific Corp. The additional investment capital will be used to advance the clinical development of the Amaranth Fortitude drug-eluting bioresorbable scaffold in a planned international clinical study and subsequent application for CE marking. In addition, the funding will support continued development of the next-generation Fortitude bioresorbable scaffold, which will have thinner struts than any currently available polymeric bioresorbable scaffold.
"The properties of the proprietary polymer and the unique manufacturing processes that we developed have allowed us to produce a scaffold with mechanical strength and durability which we believe exceeds that of all currently available bioresorbable scaffolds,” said Kamal Ramzipoor, CEO, Amaranth.
The non-drug-eluting Fortitude scaffold was previously evaluated in a study of 13 patients with symptomatic coronary artery disease (CAD), results of which were presented at the annual Transcatheter Cardiovascular Therapeutics (TCT) meeting Oct. 27, 2013. The data suggested that the Fortitude scaffold maintained its mechanical integrity, with late lumen loss comparable to that observed with bare metal stents.
The scaffold is designed to afford the strength of metal stents to assist the artery during the remodeling process following an interventional procedure, without leaving behind a permanent implant with inherent clinical limitations.
In 2014, Amaranth will begin enrolling a second cohort of patients to evaluate a drug-eluting Fortitude scaffold.
For more information: www.amaranthmedical.com